Generated: 2026-02-11T07:30:34 | Snapshot: 2026-02-10 | 241 Active Deals
| Deal | Assignee | Stage | Value | Prob % | Expected | Category | Score Breakdown |
|---|---|---|---|---|---|---|---|
| Etsilat | Adel Baluch | Discovery | 10% | €500,000 | 76% | €380,000 | Strong | Vel: 20/20 | DM: 5/20 | Act: 20/20 | Com: 8/15 | Age: 15/15 | Call: -/10 |
| Dronline | Adel Baluch | Discovery | 10% | €300,000 | 73% | €219,000 | Strong | Vel: 20/20 | DM: 5/20 | Act: 20/20 | Com: 8/15 | Age: 15/15 | Call: 5/10 |
| PracticePlusGroup | Adel Baluch | Discovery | 10% | €350,000 | 73% | €255,500 | Strong | Vel: 18/20 | DM: 5/20 | Act: 20/20 | Com: 8/15 | Age: 15/15 | Call: -/10 |
| Pfizer - Nurtec | Eran Desheh | Discovery | 10% | €500,000 | 70% | €350,000 | Strong | Vel: 20/20 | DM: 5/20 | Act: 18/20 | Com: 8/15 | Age: 15/15 | Call: 4/10 |
| GHOL | Johannes Vonhuelsen | Qualification | 5% | €0 | 67% | €0 | Healthy | Vel: 14/20 | DM: 5/20 | Act: 18/20 | Com: 8/15 | Age: 15/15 | Call: -/10 |
| Biogen - Vumerity | Usaid Cheema | Qualification | 5% | €500,000 | 54% | €270,000 | Healthy | Vel: 6/20 | DM: 12/20 | Act: 18/20 | Com: 8/15 | Age: 6/15 | Call: 4/10 |
| Bayer Visanne Patient Finder | Karen VanOverberghe | Qualification | 5% | €210,861 | 50% | €105,430 | Healthy | Vel: 6/20 | DM: 5/20 | Act: 20/20 | Com: 8/15 | Age: 6/15 | Call: 5/10 |
| Takeda | Narcolepsy | investigational | US - Phase | Usaid Cheema | Qualification | 5% | €5,040,522 | 50% | €2,520,261 | Healthy | Vel: 6/20 | DM: 5/20 | Act: 20/20 | Com: 8/15 | Age: 6/15 | Call: 5/10 |
| BMS - Patient finder Camzyos | Eran Desheh | Discovery | 10% | €250,000 | 49% | €122,500 | At Risk | Vel: 6/20 | DM: 5/20 | Act: 18/20 | Com: 8/15 | Age: 6/15 | Call: 6/10 |
| Doctor Care Anywhere | Adel Baluch | Qualification | €350,000 | 49% | €171,500 | At Risk | Vel: 14/20 | DM: 5/20 | Act: 2/20 | Com: 8/15 | Age: 15/15 | Call: 5/10 |
| GSK Product Exploration | Karen VanOverberghe | Qualification | 5% | €210,022 | 49% | €102,911 | At Risk | Vel: 6/20 | DM: 5/20 | Act: 20/20 | Com: 8/15 | Age: 6/15 | Call: 4/10 |
| Ipsen Patient Finder | Karen VanOverberghe | Qualification | 5% | €210,022 | 49% | €102,911 | At Risk | Vel: 6/20 | DM: 5/20 | Act: 20/20 | Com: 8/15 | Age: 6/15 | Call: 4/10 |
| Merck | Oncology & PAH | Keytruda & Winrevair | US | Karen VanOverberghe | Qualification | 5% | €420,044 | 49% | €205,821 | At Risk | Vel: 6/20 | DM: 5/20 | Act: 18/20 | Com: 8/15 | Age: 6/15 | Call: 6/10 |
| Dubai Health (Phase 1) | Simon Wolpert | Qualification | 5% | €1,250,000 | 48% | €600,000 | At Risk | Vel: 6/20 | DM: 5/20 | Act: 18/20 | Com: 8/15 | Age: 6/15 | Call: 5/10 |
| Merck Patient Finder Portfolio Exploration | Karen VanOverberghe | Qualification | 5% | €210,021 | 48% | €100,810 | At Risk | Vel: 6/20 | DM: 5/20 | Act: 18/20 | Com: 8/15 | Age: 6/15 | Call: 5/10 |
| MSD | PAH | SOTATERCEPT | DE - Phase 2 | Usaid Cheema | Qualification | 5% | €6,000,000 | 48% | €2,880,000 | At Risk | Vel: 6/20 | DM: 5/20 | Act: 18/20 | Com: 8/15 | Age: 6/15 | Call: 5/10 |
| Philipps-Universität Marburg / Universitätskliniku | Johannes Vonhuelsen | Qualification | 5% | €0 | 48% | €0 | At Risk | Vel: 6/20 | DM: 5/20 | Act: 18/20 | Com: 8/15 | Age: 6/15 | Call: -/10 |
| Resmed Phase 2 | Jacob Plummer | Qualification | 5% | €2,520,261 | 47% | €1,184,523 | At Risk | Vel: 6/20 | DM: 5/20 | Act: 18/20 | Com: 8/15 | Age: 6/15 | Call: 4/10 |
| SANOFI | Diabetes | TZIELD | US - Phase 2 | Eran Desheh | Discovery | 10% | €2,520,261 | 47% | €1,184,523 | At Risk | Vel: 6/20 | DM: 5/20 | Act: 18/20 | Com: 8/15 | Age: 6/15 | Call: 4/10 |
| UCB Pharma S.A.  - Bimzelx | Eran Desheh | Qualification | 5% | €500,000 | 47% | €235,000 | At Risk | Vel: 6/20 | DM: 5/20 | Act: 18/20 | Com: 8/15 | Age: 6/15 | Call: 4/10 |
| UCB | TK2D | investigational | US - Phase 2 | Jacob Plummer | Qualification | 5% | €5,040,522 | 47% | €2,369,045 | At Risk | Vel: 6/20 | DM: 5/20 | Act: 18/20 | Com: 8/15 | Age: 6/15 | Call: 4/10 |
| AstraZeneca | aHUS, PNH, HPP | UAE - Phase 2 | Eran Desheh | Qualification | 5% | €5,040,522 | 46% | €2,318,640 | At Risk | Vel: 6/20 | DM: 12/20 | Act: 10/20 | Com: 8/15 | Age: 6/15 | Call: 4/10 |
| AstraZeneca | ATTR-CM | UAE - Phase 2 | Eran Desheh | Qualification | 5% | €5,040,522 | 46% | €2,318,640 | At Risk | Vel: 6/20 | DM: 12/20 | Act: 10/20 | Com: 8/15 | Age: 6/15 | Call: 4/10 |
| Biogen - leqembi | Usaid Cheema | Qualification | 5% | €500,000 | 46% | €230,000 | At Risk | Vel: 6/20 | DM: 12/20 | Act: 10/20 | Com: 8/15 | Age: 6/15 | Call: 4/10 |
| AbbVie - Rinvoq | Usaid Cheema | Qualification | 5% | €420,044 | 44% | €184,819 | At Risk | Vel: 6/20 | DM: 10/20 | Act: 10/20 | Com: 8/15 | Age: 6/15 | Call: -/10 |
| AbbVie - Vraylar | Usaid Cheema | Qualification | 5% | €500,000 | 44% | €220,000 | At Risk | Vel: 6/20 | DM: 10/20 | Act: 10/20 | Com: 8/15 | Age: 6/15 | Call: -/10 |
| Biogen Germany FA extension | Eran Desheh | Discovery | 10% | €2,100,000 | 44% | €924,000 | At Risk | Vel: 2/20 | DM: 12/20 | Act: 18/20 | Com: 8/15 | Age: 0/15 | Call: 4/10 |
| Biogen Italy | Eran Desheh | Qualification | 5% | €350,000 | 44% | €154,000 | At Risk | Vel: 2/20 | DM: 12/20 | Act: 18/20 | Com: 8/15 | Age: 0/15 | Call: 4/10 |
| Biogen | Friedreichs Ataxia | Global - Phase 2 | Eran Desheh | Qualification | 5% | €6,000,000 | 44% | €2,640,000 | At Risk | Vel: 2/20 | DM: 12/20 | Act: 18/20 | Com: 8/15 | Age: 0/15 | Call: 4/10 |
| Boehringer Ingelheim Ofev Patient Finder | Karen VanOverberghe | Qualification | 5% | €126,013 | 44% | €55,446 | At Risk | Vel: 2/20 | DM: 7/20 | Act: 20/20 | Com: 8/15 | Age: 3/15 | Call: 4/10 |
| GNAL | Simon Wolpert | Qualification | 5% | €20,500,000 | 43% | €8,815,000 | At Risk | Vel: 6/20 | DM: 5/20 | Act: 14/20 | Com: 8/15 | Age: 6/15 | Call: 4/10 |
| Sumitomo-Gemtesa Patient FInder | Karen VanOverberghe | Qualification | 5% | €210,022 | 42% | €88,209 | At Risk | Vel: 2/20 | DM: 5/20 | Act: 20/20 | Com: 8/15 | Age: 3/15 | Call: 4/10 |
| Alexion Pharmaceuticals - Ultomiris | Usaid Cheema | Qualification | 5% | €500,000 | 41% | €205,000 | At Risk | Vel: 6/20 | DM: 7/20 | Act: 10/20 | Com: 8/15 | Age: 6/15 | Call: -/10 |
| Bayer US - Lynkuet (Elinzanetant) | Karen VanOverberghe | Discovery | 10% | €420,044 | 41% | €172,218 | At Risk | Vel: 2/20 | DM: 5/20 | Act: 20/20 | Com: 8/15 | Age: 0/15 | Call: 6/10 |
| Bayer US Nubeqa | Karen VanOverberghe | Discovery | 10% | €420,044 | 41% | €172,218 | At Risk | Vel: 2/20 | DM: 5/20 | Act: 20/20 | Com: 8/15 | Age: 0/15 | Call: 6/10 |
| HCA-UK | Adel Baluch | Discovery | 10% | €0 | 41% | €0 | At Risk | Vel: 2/20 | DM: 5/20 | Act: 20/20 | Com: 8/15 | Age: 0/15 | Call: 6/10 |
| Kyowa Kirin - Phase 1 | Eran Desheh | Discovery | 10% | €500,000 | 41% | €205,000 | At Risk | Vel: 2/20 | DM: 5/20 | Act: 18/20 | Com: 8/15 | Age: 3/15 | Call: 5/10 |
| NHS England | Adel Baluch | Discovery | 10% | €574,730 | 41% | €235,640 | At Risk | Vel: 2/20 | DM: 5/20 | Act: 20/20 | Com: 8/15 | Age: 0/15 | Call: 6/10 |
| BMS Portfolio Exploration Digital Health Team Pati | Karen VanOverberghe | Qualification | 5% | €210,022 | 40% | €84,009 | At Risk | Vel: 6/20 | DM: 5/20 | Act: 10/20 | Com: 8/15 | Age: 6/15 | Call: 5/10 |
| Glenmark Pharma | Jacob Plummer | Qualification | 5% | €1 | 40% | €0 | At Risk | Vel: 6/20 | DM: 5/20 | Act: 10/20 | Com: 8/15 | Age: 6/15 | Call: 5/10 |
| Merck Patient Finder PAH(Oncology) Winrevair US | Karen VanOverberghe | Qualification | 5% | €420,044 | 40% | €168,017 | At Risk | Vel: 2/20 | DM: 5/20 | Act: 20/20 | Com: 8/15 | Age: 0/15 | Call: 5/10 |
| Ministry of National Guard Health Affairs (Saudi A | Adel Baluch | Discovery | 10% | €500,000 | 40% | €200,000 | At Risk | Vel: 2/20 | DM: 5/20 | Act: 20/20 | Com: 8/15 | Age: 0/15 | Call: 5/10 |
| Obeikan Health Care | Adel Baluch | Discovery | 10% | €350,000 | 40% | €140,000 | At Risk | Vel: 2/20 | DM: 5/20 | Act: 20/20 | Com: 8/15 | Age: 0/15 | Call: 5/10 |
| Pure Health UAE | Adel Baluch | Discovery | 10% | €500,000 | 40% | €200,000 | At Risk | Vel: 2/20 | DM: 5/20 | Act: 20/20 | Com: 8/15 | Age: 0/15 | Call: 5/10 |
| Takeda - Alunbrig | Usaid Cheema | Qualification | 5% | €500,000 | 40% | €200,000 | At Risk | Vel: 6/20 | DM: 5/20 | Act: 10/20 | Com: 8/15 | Age: 6/15 | Call: 5/10 |
| Takeda - Eohilia | Usaid Cheema | Qualification | 5% | €420,044 | 40% | €168,017 | At Risk | Vel: 6/20 | DM: 5/20 | Act: 10/20 | Com: 8/15 | Age: 6/15 | Call: 5/10 |
| Takeda - Oveporexton | Usaid Cheema | Qualification | 5% | €420,044 | 40% | €168,017 | At Risk | Vel: 6/20 | DM: 5/20 | Act: 10/20 | Com: 8/15 | Age: 6/15 | Call: 5/10 |
| BMS Breyanzi Patient Finder | Karen VanOverberghe | Qualification | 5% | €250,000 | 39% | €97,500 | At Risk | Vel: 6/20 | DM: 5/20 | Act: 10/20 | Com: 8/15 | Age: 6/15 | Call: 4/10 |
| Genentach | Ocrevus | Usaid Cheema | Qualification | 5% | €420,044 | 39% | €163,817 | At Risk | Vel: 6/20 | DM: 5/20 | Act: 10/20 | Com: 8/15 | Age: 6/15 | Call: -/10 |
| Genentech - Esbriet | Usaid Cheema | Qualification | 5% | €500,000 | 39% | €195,000 | At Risk | Vel: 6/20 | DM: 5/20 | Act: 10/20 | Com: 8/15 | Age: 6/15 | Call: -/10 |
| Genentech - Xolair | Usaid Cheema | Qualification | 5% | €500,000 | 39% | €195,000 | At Risk | Vel: 6/20 | DM: 5/20 | Act: 10/20 | Com: 8/15 | Age: 6/15 | Call: -/10 |
| HCF Hospitals Contribution Fund | Jacob Plummer | Qualification | 5% | €800,000 | 39% | €312,000 | At Risk | Vel: 6/20 | DM: 5/20 | Act: 10/20 | Com: 8/15 | Age: 6/15 | Call: -/10 |
| Ipsen - Sohonos | Eran Desheh | Qualification | 5% | €420,044 | 39% | €163,817 | At Risk | Vel: 6/20 | DM: 5/20 | Act: 10/20 | Com: 8/15 | Age: 6/15 | Call: 4/10 |
| J&J Immunology (Stelara) US - Phase 1 | Eran Desheh | Qualification | 5% | €420,044 | 39% | €163,817 | At Risk | Vel: 6/20 | DM: 5/20 | Act: 10/20 | Com: 8/15 | Age: 6/15 | Call: -/10 |
| J&J Immunology (Tremfya) US - Phase 1 | Eran Desheh | Qualification | 5% | €420,044 | 39% | €163,817 | At Risk | Vel: 6/20 | DM: 5/20 | Act: 10/20 | Com: 8/15 | Age: 6/15 | Call: -/10 |
| Kings College London, Saudi Arabia | Adel Baluch | Proposal | 30% | €402,311 | 39% | €156,901 | At Risk | Vel: 2/20 | DM: 5/20 | Act: 20/20 | Com: 8/15 | Age: 0/15 | Call: -/10 |
| Lilly Kisunla Patient Finder | Karen VanOverberghe | Qualification | 5% | €210,022 | 39% | €81,908 | At Risk | Vel: 2/20 | DM: 5/20 | Act: 20/20 | Com: 8/15 | Age: 0/15 | Call: 4/10 |
| Novartis - Cosentyx (E2E Care Journey) | Karen VanOverberghe | Qualification | 5% | €210,022 | 39% | €81,908 | At Risk | Vel: 6/20 | DM: 5/20 | Act: 10/20 | Com: 8/15 | Age: 6/15 | Call: -/10 |
| Novartis Fabhalta Patient Finder | Karen VanOverberghe | Qualification | 5% | €500,000 | 39% | €195,000 | At Risk | Vel: 6/20 | DM: 5/20 | Act: 10/20 | Com: 8/15 | Age: 6/15 | Call: 4/10 |
| Novartis Kesimpta Patient Finder | Karen VanOverberghe | Qualification | 5% | €500,000 | 39% | €195,000 | At Risk | Vel: 6/20 | DM: 5/20 | Act: 10/20 | Com: 8/15 | Age: 6/15 | Call: 4/10 |
| Roche - Piasky | Usaid Cheema | Qualification | 5% | €500,000 | 39% | €195,000 | At Risk | Vel: 6/20 | DM: 5/20 | Act: 10/20 | Com: 8/15 | Age: 6/15 | Call: -/10 |
| Roche | Neurology & Oncology | Global | Eran Desheh | Qualification | 5% | €420,044 | 39% | €163,817 | At Risk | Vel: 6/20 | DM: 5/20 | Act: 10/20 | Com: 8/15 | Age: 6/15 | Call: -/10 |
| Roche - Evrysdi | Usaid Cheema | Qualification | 5% | €500,000 | 39% | €195,000 | At Risk | Vel: 6/20 | DM: 5/20 | Act: 10/20 | Com: 8/15 | Age: 6/15 | Call: -/10 |
| Voramedic | Johannes Vonhuelsen | Contracting | 80% | €200,000 | 39% | €78,000 | At Risk | Vel: 2/20 | DM: 5/20 | Act: 20/20 | Com: 8/15 | Age: 0/15 | Call: -/10 |
| AstraZeneca - Breztri Aerosphere | Usaid Cheema | Qualification | 5% | €420,044 | 38% | €159,617 | At Risk | Vel: 6/20 | DM: 12/20 | Act: 2/20 | Com: 8/15 | Age: 6/15 | Call: 4/10 |
| AstraZeneca - Calquence | Usaid Cheema | Qualification | 5% | €420,044 | 38% | €159,617 | At Risk | Vel: 6/20 | DM: 12/20 | Act: 2/20 | Com: 8/15 | Age: 6/15 | Call: 4/10 |
| AstraZeneca - Farxiga | Usaid Cheema | Qualification | 5% | €420,044 | 38% | €159,617 | At Risk | Vel: 6/20 | DM: 12/20 | Act: 2/20 | Com: 8/15 | Age: 6/15 | Call: 4/10 |
| Astrazeneca - Wainua | Usaid Cheema | Qualification | 5% | €500,000 | 38% | €190,000 | At Risk | Vel: 6/20 | DM: 12/20 | Act: 2/20 | Com: 8/15 | Age: 6/15 | Call: 4/10 |
| AstraZeneca AB - Wainzua | Eran Desheh | Qualification | 5% | €500,000 | 38% | €190,000 | At Risk | Vel: 6/20 | DM: 12/20 | Act: 2/20 | Com: 8/15 | Age: 6/15 | Call: 4/10 |
| AstraZeneca | Saphnelo | Systemic lupus erythemato | Jacob Plummer | Qualification | 5% | €420,044 | 38% | €159,617 | At Risk | Vel: 6/20 | DM: 12/20 | Act: 2/20 | Com: 8/15 | Age: 6/15 | Call: 4/10 |
| Biogen - Spinraza | Usaid Cheema | Qualification | 5% | €500,000 | 38% | €190,000 | At Risk | Vel: 6/20 | DM: 12/20 | Act: 2/20 | Com: 8/15 | Age: 6/15 | Call: 4/10 |
| MSD | PAH | SOTATERCEPT | DE | Eran Desheh | Contracting | 80% | €50,000 | 38% | €19,000 | At Risk | Vel: 2/20 | DM: 5/20 | Act: 18/20 | Com: 8/15 | Age: 0/15 | Call: 5/10 |
| Stanford Health Care | Simon Wolpert | Qualification | 5% | €1,428,148 | 38% | €542,696 | At Risk | Vel: 2/20 | DM: 5/20 | Act: 18/20 | Com: 8/15 | Age: 0/15 | Call: 5/10 |
| Takeda | Narcolepsy | investigational | US | Eran Desheh | Discovery | 10% | €420,044 | 38% | €159,617 | At Risk | Vel: 2/20 | DM: 5/20 | Act: 18/20 | Com: 8/15 | Age: 0/15 | Call: 5/10 |
| Aetna a CVS Health Company | Simon Wolpert | Qualification | 5% | €252,026 | 37% | €93,250 | At Risk | Vel: 6/20 | DM: 10/20 | Act: 2/20 | Com: 8/15 | Age: 6/15 | Call: 5/10 |
| Amicus - Galafold (Fabry) | Karen VanOverberghe | Qualification | 5% | €8,400 | 37% | €3,108 | At Risk | Vel: 6/20 | DM: 7/20 | Act: 6/20 | Com: 8/15 | Age: 6/15 | Call: -/10 |
| Malaffi Super App | Simon Wolpert | Qualification | €8,000,000 | 37% | €2,960,000 | At Risk | Vel: 2/20 | DM: 5/20 | Act: 18/20 | Com: 8/15 | Age: 0/15 | Call: 4/10 |
| Newfoundland DFD (via Orion) | Simon Wolpert | Discovery | 10% | €1,362,841 | 37% | €504,251 | At Risk | Vel: 2/20 | DM: 5/20 | Act: 18/20 | Com: 8/15 | Age: 0/15 | Call: 4/10 |
| UCB Bimzelx (HS) Peer to Peer Engagement Patient F | Karen VanOverberghe | Discovery | 10% | €420 | 37% | €155 | At Risk | Vel: 2/20 | DM: 5/20 | Act: 18/20 | Com: 8/15 | Age: 0/15 | Call: 4/10 |
| UCB | BIMZELX | HS |Ex-US | Jacob Plummer | Discovery | 10% | €420,044 | 37% | €155,416 | At Risk | Vel: 2/20 | DM: 5/20 | Act: 18/20 | Com: 8/15 | Age: 0/15 | Call: 4/10 |
| UCB | TK2D | investigational | US | Jacob Plummer | Discovery | 10% | €420,044 | 37% | €155,416 | At Risk | Vel: 2/20 | DM: 5/20 | Act: 18/20 | Com: 8/15 | Age: 0/15 | Call: 4/10 |
| AbbVie - Botox | Usaid Cheema | Qualification | 5% | €420,044 | 36% | €151,216 | At Risk | Vel: 6/20 | DM: 10/20 | Act: 2/20 | Com: 8/15 | Age: 6/15 | Call: -/10 |
| Alkermes - Libalvi | Usaid Cheema | Qualification | 5% | €500,000 | 36% | €180,000 | At Risk | Vel: 6/20 | DM: 2/20 | Act: 10/20 | Com: 8/15 | Age: 6/15 | Call: -/10 |
| AstraZeneca | PNH | UAE | Eran Desheh | Discovery | 10% | €420,044 | 36% | €151,216 | At Risk | Vel: 2/20 | DM: 12/20 | Act: 10/20 | Com: 8/15 | Age: 0/15 | Call: 4/10 |
| Biogen US | Ashley Cudini | Discovery | 10% | €420,044 | 36% | €151,216 | At Risk | Vel: 2/20 | DM: 12/20 | Act: 10/20 | Com: 8/15 | Age: 0/15 | Call: 4/10 |
| Bristol Myers Squibb | Opdivo | Melanoma | Karen VanOverberghe | Qualification | 5% | €420,044 | 36% | €151,216 | At Risk | Vel: 6/20 | DM: 10/20 | Act: 2/20 | Com: 8/15 | Age: 6/15 | Call: -/10 |
| Novartis Rhapsido (Hives no known triggers) Patien | Karen VanOverberghe | Qualification | 5% | €250,000 | 36% | €90,000 | At Risk | Vel: 2/20 | DM: 5/20 | Act: 14/20 | Com: 8/15 | Age: 3/15 | Call: 4/10 |
| Amgen Ultrarare US -Actimmune (CGD) | Karen VanOverberghe | Discovery | 10% | €210,022 | 35% | €73,508 | At Risk | Vel: 2/20 | DM: 10/20 | Act: 10/20 | Com: 8/15 | Age: 3/15 | Call: 2/10 |
| BMS - Zeposia | Usaid Cheema | Qualification | 5% | €500,000 | 35% | €175,000 | At Risk | Vel: 6/20 | DM: 5/20 | Act: 4/20 | Com: 8/15 | Age: 6/15 | Call: 6/10 |
| BUPA UK | Johannes Vonhuelsen | Contracting | 80% | €300,000 | 35% | €105,000 | At Risk | Vel: 2/20 | DM: 7/20 | Act: 14/20 | Com: 8/15 | Age: 0/15 | Call: 4/10 |
| Incyte Jakafi Patient Finder | Karen VanOverberghe | Qualification | 5% | €420,044 | 35% | €147,015 | At Risk | Vel: 6/20 | DM: 5/20 | Act: 6/20 | Com: 8/15 | Age: 6/15 | Call: 4/10 |
| Amgen - Evenity | Usaid Cheema | Qualification | 5% | €500,000 | 34% | €170,000 | At Risk | Vel: 6/20 | DM: 10/20 | Act: 2/20 | Com: 8/15 | Age: 6/15 | Call: 2/10 |
| Astellas - MYRBETIQ | Usaid Cheema | Qualification | 5% | €500,000 | 34% | €170,000 | At Risk | Vel: 6/20 | DM: 7/20 | Act: 4/20 | Com: 8/15 | Age: 6/15 | Call: -/10 |
| Blue Shield of California | Simon Wolpert | Proposal | 30% | €5,460,566 | 34% | €1,856,592 | At Risk | Vel: 2/20 | DM: 7/20 | Act: 14/20 | Com: 8/15 | Age: 0/15 | Call: -/10 |
| Ontario SOW 9 Enhancement - OHT Mapping - Planning | Simon Wolpert | Proposal | 30% | €123,895 | 34% | €42,124 | At Risk | Vel: 2/20 | DM: 5/20 | Act: 14/20 | Com: 8/15 | Age: 0/15 | Call: 5/10 |
| Teva Pharmaceutical Industries | Austedo | Tardive | Usaid Cheema | Qualification | 5% | €420,044 | 34% | €142,815 | At Risk | Vel: 6/20 | DM: 5/20 | Act: 6/20 | Com: 8/15 | Age: 6/15 | Call: -/10 |
| BMS - Atrial fibrilation and thrombosis | Eran Desheh | Qualification | 5% | €500,000 | 33% | €165,000 | At Risk | Vel: 6/20 | DM: 5/20 | Act: 2/20 | Com: 8/15 | Age: 6/15 | Call: 6/10 |
| BMS - Inrebic | Eran Desheh | Qualification | 5% | €500,000 | 33% | €165,000 | At Risk | Vel: 6/20 | DM: 5/20 | Act: 2/20 | Com: 8/15 | Age: 6/15 | Call: 6/10 |
| BMS - Juvenile Idiopathic Arthritis (JIA) | Eran Desheh | Qualification | 5% | €500,000 | 33% | €165,000 | At Risk | Vel: 6/20 | DM: 5/20 | Act: 2/20 | Com: 8/15 | Age: 6/15 | Call: 6/10 |
| BMS - Psoriatic arthritis | Eran Desheh | Qualification | 5% | €500,000 | 33% | €165,000 | At Risk | Vel: 6/20 | DM: 5/20 | Act: 2/20 | Com: 8/15 | Age: 6/15 | Call: 6/10 |
| BMS - Rheumatoid arthritis | Eran Desheh | Qualification | 5% | €500,000 | 33% | €165,000 | At Risk | Vel: 6/20 | DM: 5/20 | Act: 2/20 | Com: 8/15 | Age: 6/15 | Call: 6/10 |
| Clinical University Childrens Hospital, Latvia (BU | Adel Baluch | Discovery | 10% | €1,000,000 | 33% | €330,000 | At Risk | Vel: 2/20 | DM: 5/20 | Act: 14/20 | Com: 8/15 | Age: 0/15 | Call: 4/10 |
| Merck - Gardasil 9 | Usaid Cheema | Qualification | 5% | €420,044 | 33% | €138,614 | At Risk | Vel: 6/20 | DM: 5/20 | Act: 2/20 | Com: 8/15 | Age: 6/15 | Call: 6/10 |
| Merck - KEYTRUDA | Usaid Cheema | Qualification | 5% | €500,000 | 33% | €165,000 | At Risk | Vel: 6/20 | DM: 5/20 | Act: 2/20 | Com: 8/15 | Age: 6/15 | Call: 6/10 |
| Merck - Welireg | Usaid Cheema | Qualification | 5% | €500,000 | 33% | €165,000 | At Risk | Vel: 6/20 | DM: 5/20 | Act: 2/20 | Com: 8/15 | Age: 6/15 | Call: 6/10 |
| Ontario SOW10 Enhancement Opportunity - Condition | Simon Wolpert | Proposal | 30% | €390,268 | 33% | €128,789 | At Risk | Vel: 2/20 | DM: 5/20 | Act: 14/20 | Com: 8/15 | Age: 0/15 | Call: 4/10 |
| Alexion Pharmaceuticals - Koselugo | Usaid Cheema | Qualification | 5% | €500,000 | 32% | €160,000 | At Risk | Vel: 6/20 | DM: 7/20 | Act: 2/20 | Com: 8/15 | Age: 6/15 | Call: -/10 |
| Angelini Pharma S.p.A - Ontozry | Eran Desheh | Qualification | 5% | €500,000 | 32% | €160,000 | At Risk | Vel: 6/20 | DM: 5/20 | Act: 2/20 | Com: 8/15 | Age: 6/15 | Call: 5/10 |
| Astellas - VEOZAH | Usaid Cheema | Qualification | 5% | €500,000 | 32% | €160,000 | At Risk | Vel: 6/20 | DM: 7/20 | Act: 2/20 | Com: 8/15 | Age: 6/15 | Call: -/10 |
| Crohns Colitis Foundation | Jacob Plummer | Qualification | 5% | €420,044 | 32% | €134,414 | At Risk | Vel: 6/20 | DM: 5/20 | Act: 4/20 | Com: 8/15 | Age: 6/15 | Call: -/10 |
| Eli Lilly Nederland B.V. - Omvoh | Qualification | 5% | €500,000 | 32% | €160,000 | At Risk | Vel: 6/20 | DM: 5/20 | Act: 2/20 | Com: 8/15 | Age: 6/15 | Call: 5/10 | |
| GoodApple - Menopause RFP | Jacob Plummer | Discovery | 10% | €0 | 32% | €0 | At Risk | Vel: 2/20 | DM: 5/20 | Act: 10/20 | Com: 8/15 | Age: 3/15 | Call: 4/10 |
| J&J - Invega | Usaid Cheema | Qualification | 5% | €500,000 | 32% | €160,000 | At Risk | Vel: 6/20 | DM: 5/20 | Act: 4/20 | Com: 8/15 | Age: 6/15 | Call: -/10 |
| LEO Pharma A/S - Adtralza | Eran Desheh | Qualification | 5% | €500,000 | 32% | €160,000 | At Risk | Vel: 6/20 | DM: 5/20 | Act: 2/20 | Com: 8/15 | Age: 6/15 | Call: 5/10 |
| LEO Pharma A/S - Anzupgo | Eran Desheh | Qualification | 5% | €500,000 | 32% | €160,000 | At Risk | Vel: 6/20 | DM: 5/20 | Act: 2/20 | Com: 8/15 | Age: 6/15 | Call: 5/10 |
| Lilly Zepbound OSA Ptient Finder | Karen VanOverberghe | Qualification | 5% | €210,022 | 32% | €67,207 | At Risk | Vel: 2/20 | DM: 5/20 | Act: 10/20 | Com: 8/15 | Age: 3/15 | Call: 4/10 |
| Novartis HS Italy Upsell | Eran Desheh | Qualification | 5% | €105,000 | 32% | €33,600 | At Risk | Vel: 2/20 | DM: 5/20 | Act: 14/20 | Com: 8/15 | Age: 0/15 | Call: -/10 |
| Novartis HS Spain Upsell | Eran Desheh | Qualification | 5% | €105,000 | 32% | €33,600 | At Risk | Vel: 2/20 | DM: 5/20 | Act: 14/20 | Com: 8/15 | Age: 0/15 | Call: -/10 |
| Ontario Enhancement - Gender Neutrality | Simon Wolpert | Proposal | 30% | €216,816 | 32% | €69,381 | At Risk | Vel: 2/20 | DM: 5/20 | Act: 14/20 | Com: 8/15 | Age: 0/15 | Call: -/10 |
| Ontario Enhancement - Health811 Post Login Experie | Simon Wolpert | Discovery | 10% | €309,737 | 32% | €99,116 | At Risk | Vel: 2/20 | DM: 5/20 | Act: 14/20 | Com: 8/15 | Age: 0/15 | Call: -/10 |
| Ontario Enhancements | Simon Wolpert | Proposal | 30% | €1,982,315 | 32% | €634,341 | At Risk | Vel: 2/20 | DM: 5/20 | Act: 14/20 | Com: 8/15 | Age: 0/15 | Call: -/10 |
| Ontario SOW9 Enhancement - Trusted User (Deferred | Simon Wolpert | Discovery | 10% | €100,000 | 32% | €32,000 | At Risk | Vel: 2/20 | DM: 5/20 | Act: 14/20 | Com: 8/15 | Age: 0/15 | Call: -/10 |
| Patient Finder for Temple Health | Randal Whitmore | Qualification | 5% | €420,044 | 32% | €134,414 | At Risk | Vel: 6/20 | DM: 5/20 | Act: 2/20 | Com: 8/15 | Age: 6/15 | Call: 5/10 |
| Plusultra pharma GmbH - Hyftor | Eran Desheh | Qualification | 5% | €500,000 | 32% | €160,000 | At Risk | Vel: 6/20 | DM: 5/20 | Act: 2/20 | Com: 8/15 | Age: 6/15 | Call: 5/10 |
| Takeda - Zasocitinib | Usaid Cheema | Qualification | 5% | €500,000 | 32% | €160,000 | At Risk | Vel: 6/20 | DM: 5/20 | Act: 2/20 | Com: 8/15 | Age: 6/15 | Call: 5/10 |
| ALK-Abelló A/S - Eurneffy | Eran Desheh | Qualification | 5% | €500,000 | 31% | €155,000 | At Risk | Vel: 6/20 | DM: 5/20 | Act: 2/20 | Com: 8/15 | Age: 6/15 | Call: 4/10 |
| Bayer | ATTR-CM | DE | Jacob Plummer | Qualification | 5% | €420,044 | 31% | €130,213 | At Risk | Vel: 2/20 | DM: 5/20 | Act: 10/20 | Com: 8/15 | Age: 0/15 | Call: 6/10 |
| BMS - US | Jacob Plummer | Qualification | 5% | €420,044 | 31% | €130,213 | At Risk | Vel: 2/20 | DM: 5/20 | Act: 10/20 | Com: 8/15 | Age: 0/15 | Call: 6/10 |
| BMS Cobenfy Patient Finder | Karen VanOverberghe | Qualification | 5% | €420,044 | 31% | €130,213 | At Risk | Vel: 6/20 | DM: 5/20 | Act: 2/20 | Com: 8/15 | Age: 6/15 | Call: 4/10 |
| Novo Nordisk A/S - Alhemo | Eran Desheh | Qualification | 5% | €500,000 | 31% | €155,000 | At Risk | Vel: 6/20 | DM: 5/20 | Act: 2/20 | Com: 8/15 | Age: 6/15 | Call: 4/10 |
| Novo Nordisk A/S - Sogroya | Eran Desheh | Qualification | 5% | €500,000 | 31% | €155,000 | At Risk | Vel: 6/20 | DM: 5/20 | Act: 2/20 | Com: 8/15 | Age: 6/15 | Call: 4/10 |
| Novo Nordisk A/S - Zegalogue | Eran Desheh | Qualification | 5% | €500,000 | 31% | €155,000 | At Risk | Vel: 6/20 | DM: 5/20 | Act: 2/20 | Com: 8/15 | Age: 6/15 | Call: 4/10 |
| Pfizer Europe MA EEIG - Litfulo | Eran Desheh | Qualification | 5% | €500,000 | 31% | €155,000 | At Risk | Vel: 6/20 | DM: 5/20 | Act: 2/20 | Com: 8/15 | Age: 6/15 | Call: 4/10 |
| Pfizer Europe MA EEIG - Cibinqo | Eran Desheh | Qualification | 5% | €500,000 | 31% | €155,000 | At Risk | Vel: 6/20 | DM: 5/20 | Act: 2/20 | Com: 8/15 | Age: 6/15 | Call: 4/10 |
| Pfizer Europe MA EEIG - Emblaveo | Eran Desheh | Qualification | 5% | €500,000 | 31% | €155,000 | At Risk | Vel: 6/20 | DM: 5/20 | Act: 2/20 | Com: 8/15 | Age: 6/15 | Call: 4/10 |
| Pfizer Europe MA EEIG - Hympavzi | Eran Desheh | Qualification | 5% | €500,000 | 31% | €155,000 | At Risk | Vel: 6/20 | DM: 5/20 | Act: 2/20 | Com: 8/15 | Age: 6/15 | Call: 4/10 |
| Pfizer Europe MA EEIG - Tivdak | Eran Desheh | Qualification | 5% | €500,000 | 31% | €155,000 | At Risk | Vel: 6/20 | DM: 5/20 | Act: 2/20 | Com: 8/15 | Age: 6/15 | Call: 4/10 |
| Sanofi | Nexviazyme | Pompe's disease | Usaid Cheema | Qualification | 5% | €420,044 | 31% | €130,213 | At Risk | Vel: 6/20 | DM: 5/20 | Act: 2/20 | Com: 8/15 | Age: 6/15 | Call: 4/10 |
| UCB - Neupro | Usaid Cheema | Qualification | 5% | €500,000 | 31% | €155,000 | At Risk | Vel: 6/20 | DM: 5/20 | Act: 2/20 | Com: 8/15 | Age: 6/15 | Call: 4/10 |
| UCB | Bimzelx | Psoriasis & HS | Jacob Plummer | Qualification | 5% | €420,044 | 31% | €130,213 | At Risk | Vel: 6/20 | DM: 5/20 | Act: 2/20 | Com: 8/15 | Age: 6/15 | Call: 4/10 |
| Ultragenyx Germany GmbH - Evkeeza | Eran Desheh | Qualification | 5% | €500,000 | 31% | €155,000 | At Risk | Vel: 6/20 | DM: 5/20 | Act: 2/20 | Com: 8/15 | Age: 6/15 | Call: 4/10 |
| Alexion Europe SAS - Voydeya | Eran Desheh | Qualification | 5% | €500,000 | 30% | €150,000 | At Risk | Vel: 6/20 | DM: 5/20 | Act: 2/20 | Com: 8/15 | Age: 6/15 | Call: -/10 |
| Amazon Health Services | United States | Christine Minott | Qualification | 5% | €0 | 30% | €0 | At Risk | Vel: 2/20 | DM: 5/20 | Act: 10/20 | Com: 8/15 | Age: 0/15 | Call: 5/10 |
| Amivas Ireland Ltd - Artesunate Amivas | Eran Desheh | Qualification | 5% | €500,000 | 30% | €150,000 | At Risk | Vel: 6/20 | DM: 5/20 | Act: 2/20 | Com: 8/15 | Age: 6/15 | Call: -/10 |
| Blue Cross Blue Shield Arizona | Simon Wolpert | Qualification | 5% | €1,428,148 | 30% | €428,444 | At Risk | Vel: 6/20 | DM: 5/20 | Act: 2/20 | Com: 8/15 | Age: 6/15 | Call: -/10 |
| Deciphera Pharmaceuticals (Netherlands) B.V. - Qin | Eran Desheh | Qualification | 5% | €500,000 | 30% | €150,000 | At Risk | Vel: 6/20 | DM: 5/20 | Act: 2/20 | Com: 8/15 | Age: 6/15 | Call: -/10 |
| Eli Lilly and Company | Karen VanOverberghe | Qualification | €210,022 | 30% | €63,007 | At Risk | Vel: 2/20 | DM: 5/20 | Act: 10/20 | Com: 8/15 | Age: 0/15 | Call: 5/10 |
| Galderma International - Nemluvio | Eran Desheh | Qualification | 5% | €500,000 | 30% | €150,000 | At Risk | Vel: 6/20 | DM: 5/20 | Act: 2/20 | Com: 8/15 | Age: 6/15 | Call: -/10 |
| Gedeon Richter Plc. - Ryeqo | Eran Desheh | Qualification | 5% | €500,000 | 30% | €150,000 | At Risk | Vel: 6/20 | DM: 5/20 | Act: 2/20 | Com: 8/15 | Age: 6/15 | Call: -/10 |
| Gilead - Biktarvy | Usaid Cheema | Qualification | 5% | €420,044 | 30% | €126,013 | At Risk | Vel: 6/20 | DM: 5/20 | Act: 2/20 | Com: 8/15 | Age: 6/15 | Call: -/10 |
| Gilead - Descovy | Usaid Cheema | Qualification | 5% | €420,044 | 30% | €126,013 | At Risk | Vel: 6/20 | DM: 5/20 | Act: 2/20 | Com: 8/15 | Age: 6/15 | Call: -/10 |
| GlaxoSmithKline - Xevudy | Eran Desheh | Qualification | 5% | €500,000 | 30% | €150,000 | At Risk | Vel: 6/20 | DM: 5/20 | Act: 2/20 | Com: 8/15 | Age: 6/15 | Call: -/10 |
| GlaxoSmithKline Trading Services Limited - Omjjara | Eran Desheh | Qualification | 5% | €500,000 | 30% | €150,000 | At Risk | Vel: 6/20 | DM: 5/20 | Act: 2/20 | Com: 8/15 | Age: 6/15 | Call: -/10 |
| GSK - Arexvy | Usaid Cheema | Qualification | 5% | €500,000 | 30% | €150,000 | At Risk | Vel: 6/20 | DM: 5/20 | Act: 2/20 | Com: 8/15 | Age: 6/15 | Call: 3/10 |
| GSK - Arnuity Ellipta | Usaid Cheema | Qualification | 5% | €420,044 | 30% | €126,013 | At Risk | Vel: 6/20 | DM: 5/20 | Act: 2/20 | Com: 8/15 | Age: 6/15 | Call: 3/10 |
| GSK - Flovent | Usaid Cheema | Qualification | 5% | €420,044 | 30% | €126,013 | At Risk | Vel: 6/20 | DM: 5/20 | Act: 2/20 | Com: 8/15 | Age: 6/15 | Call: 3/10 |
| GSK - Shingrix | Usaid Cheema | Qualification | 5% | €420,044 | 30% | €126,013 | At Risk | Vel: 6/20 | DM: 5/20 | Act: 2/20 | Com: 8/15 | Age: 6/15 | Call: 3/10 |
| Highmark RFI | Simon Wolpert | Qualification | 5% | €1,428,148 | 30% | €428,444 | At Risk | Vel: 6/20 | DM: 5/20 | Act: 2/20 | Com: 8/15 | Age: 6/15 | Call: -/10 |
| Incyte Biosciences Distribution B.V. - Opzelura | Eran Desheh | Qualification | 5% | €500,000 | 30% | €150,000 | At Risk | Vel: 6/20 | DM: 5/20 | Act: 2/20 | Com: 8/15 | Age: 6/15 | Call: -/10 |
| InflaRx GmbH - Gohibic | Eran Desheh | Qualification | 5% | €500,000 | 30% | €150,000 | At Risk | Vel: 6/20 | DM: 5/20 | Act: 2/20 | Com: 8/15 | Age: 6/15 | Call: -/10 |
| Janssen-Cilag International N.V. - Akeega | Eran Desheh | Qualification | 5% | €500,000 | 30% | €150,000 | At Risk | Vel: 6/20 | DM: 5/20 | Act: 2/20 | Com: 8/15 | Age: 6/15 | Call: -/10 |
| Johnson & Johnson | Tremfya | Psoriasis total | Jacob Plummer | Qualification | 5% | €420,044 | 30% | €126,013 | At Risk | Vel: 6/20 | DM: 5/20 | Act: 2/20 | Com: 8/15 | Age: 6/15 | Call: -/10 |
| Laboratoires Théa - Vevizye | Eran Desheh | Qualification | 5% | €500,000 | 30% | €150,000 | At Risk | Vel: 6/20 | DM: 5/20 | Act: 2/20 | Com: 8/15 | Age: 6/15 | Call: -/10 |
| Madrigal - Rezdiffra | Usaid Cheema | Qualification | 5% | €420,044 | 30% | €126,013 | At Risk | Vel: 6/20 | DM: 5/20 | Act: 2/20 | Com: 8/15 | Age: 6/15 | Call: -/10 |
| Medice Arzneimittel Pütter GmbH & Co. KG - Vafseo | Eran Desheh | Qualification | 5% | €500,000 | 30% | €150,000 | At Risk | Vel: 6/20 | DM: 5/20 | Act: 2/20 | Com: 8/15 | Age: 6/15 | Call: -/10 |
| Moderna Biotech Spain, S.L. - mResvia | Eran Desheh | Qualification | 5% | €500,000 | 30% | €150,000 | At Risk | Vel: 6/20 | DM: 5/20 | Act: 2/20 | Com: 8/15 | Age: 6/15 | Call: -/10 |
| Mundipharma GmbH - Rezzayo | Eran Desheh | Qualification | 5% | €500,000 | 30% | €150,000 | At Risk | Vel: 6/20 | DM: 5/20 | Act: 2/20 | Com: 8/15 | Age: 6/15 | Call: -/10 |
| Neuraxpharm Pharmaceuticals S.L. - Tuzulby | Eran Desheh | Qualification | 5% | €500,000 | 30% | €150,000 | At Risk | Vel: 6/20 | DM: 5/20 | Act: 2/20 | Com: 8/15 | Age: 6/15 | Call: -/10 |
| Norgine B.V. - Agilus | Eran Desheh | Qualification | 5% | €500,000 | 30% | €150,000 | At Risk | Vel: 6/20 | DM: 5/20 | Act: 2/20 | Com: 8/15 | Age: 6/15 | Call: -/10 |
| Novartis - Kesimpta | Usaid Cheema | Qualification | 5% | €420,044 | 30% | €126,013 | At Risk | Vel: 6/20 | DM: 5/20 | Act: 2/20 | Com: 8/15 | Age: 6/15 | Call: -/10 |
| Novartis | drug tbd | US | Eran Desheh | Qualification | 5% | €420,044 | 30% | €126,013 | At Risk | Vel: 6/20 | DM: 5/20 | Act: 2/20 | Com: 8/15 | Age: 6/15 | Call: -/10 |
| Otsuka - centanafadine | Usaid Cheema | Qualification | 5% | €420,044 | 30% | €126,013 | At Risk | Vel: 6/20 | DM: 5/20 | Act: 2/20 | Com: 8/15 | Age: 6/15 | Call: -/10 |
| Outlook Therapeutics Limited - Lytenava | Eran Desheh | Qualification | 5% | €500,000 | 30% | €150,000 | At Risk | Vel: 6/20 | DM: 5/20 | Act: 2/20 | Com: 8/15 | Age: 6/15 | Call: -/10 |
| Pfizer- Abrysvo | Usaid Cheema | Qualification | 5% | €420,044 | 30% | €126,013 | At Risk | Vel: 6/20 | DM: 5/20 | Act: 2/20 | Com: 8/15 | Age: 6/15 | Call: -/10 |
| Pfizer- Comirnaty | Usaid Cheema | Qualification | 5% | €420,044 | 30% | €126,013 | At Risk | Vel: 6/20 | DM: 5/20 | Act: 2/20 | Com: 8/15 | Age: 6/15 | Call: -/10 |
| Pfizer- Xtandi | Usaid Cheema | Qualification | 5% | €420,044 | 30% | €126,013 | At Risk | Vel: 6/20 | DM: 5/20 | Act: 2/20 | Com: 8/15 | Age: 6/15 | Call: -/10 |
| Pharming | Joenja | Activated phosphoinositide 3-k | Usaid Cheema | Qualification | 5% | €420,044 | 30% | €126,013 | At Risk | Vel: 6/20 | DM: 5/20 | Act: 2/20 | Com: 8/15 | Age: 6/15 | Call: -/10 |
| Pierre Fabre Medicament - Obgemsa | Eran Desheh | Qualification | 5% | €500,000 | 30% | €150,000 | At Risk | Vel: 6/20 | DM: 5/20 | Act: 2/20 | Com: 8/15 | Age: 6/15 | Call: -/10 |
| PROBTP Groupe | Johannes Vonhuelsen | Qualification | €0 | 30% | €0 | At Risk | Vel: 6/20 | DM: 5/20 | Act: 2/20 | Com: 8/15 | Age: 6/15 | Call: -/10 |
| Roche Registration GmbH - Xofluza | Eran Desheh | Qualification | 5% | €500,000 | 30% | €150,000 | At Risk | Vel: 6/20 | DM: 5/20 | Act: 2/20 | Com: 8/15 | Age: 6/15 | Call: -/10 |
| Roche Registration GmbH - Ronapreve | Eran Desheh | Qualification | 5% | €500,000 | 30% | €150,000 | At Risk | Vel: 6/20 | DM: 5/20 | Act: 2/20 | Com: 8/15 | Age: 6/15 | Call: -/10 |
| Santen Oy - Catiolanze | Eran Desheh | Qualification | 5% | €500,000 | 30% | €150,000 | At Risk | Vel: 6/20 | DM: 5/20 | Act: 2/20 | Com: 8/15 | Age: 6/15 | Call: -/10 |
| Santhera Pharmaceuticals (Deutschland) GmbH - Agam | Eran Desheh | Qualification | 5% | €500,000 | 30% | €150,000 | At Risk | Vel: 6/20 | DM: 5/20 | Act: 2/20 | Com: 8/15 | Age: 6/15 | Call: -/10 |
| Seqirus Netherlands B.V. - Fluad | Eran Desheh | Qualification | 5% | €500,000 | 30% | €150,000 | At Risk | Vel: 6/20 | DM: 5/20 | Act: 2/20 | Com: 8/15 | Age: 6/15 | Call: -/10 |
| SIFI SPA - Akantior | Eran Desheh | Qualification | 5% | €500,000 | 30% | €150,000 | At Risk | Vel: 6/20 | DM: 5/20 | Act: 2/20 | Com: 8/15 | Age: 6/15 | Call: 3/10 |
| Sumitomo - MYFEMBREE | Usaid Cheema | Qualification | 5% | €500,000 | 30% | €150,000 | At Risk | Vel: 6/20 | DM: 5/20 | Act: 2/20 | Com: 8/15 | Age: 6/15 | Call: -/10 |
| Sumitomo - ORGOVYX | Usaid Cheema | Qualification | 5% | €500,000 | 30% | €150,000 | At Risk | Vel: 6/20 | DM: 5/20 | Act: 2/20 | Com: 8/15 | Age: 6/15 | Call: -/10 |
| Swedish Orphan Biovitrum AB (publ) - Altuvoct | Eran Desheh | Qualification | 5% | €500,000 | 30% | €150,000 | At Risk | Vel: 6/20 | DM: 5/20 | Act: 2/20 | Com: 8/15 | Age: 6/15 | Call: -/10 |
| TAKEDA | Psoriasis & Psoriatic Arthritis (Phase 3) | Eran Desheh | Qualification | 5% | €420,044 | 30% | €126,013 | At Risk | Vel: 2/20 | DM: 5/20 | Act: 10/20 | Com: 8/15 | Age: 0/15 | Call: 5/10 |
| Teva B.V. - BroPair Spiromax | Eran Desheh | Qualification | 5% | €500,000 | 30% | €150,000 | At Risk | Vel: 6/20 | DM: 5/20 | Act: 2/20 | Com: 8/15 | Age: 6/15 | Call: -/10 |
| Teva B.V. - Seffalair Spiromax | Eran Desheh | Qualification | 5% | €500,000 | 30% | €150,000 | At Risk | Vel: 6/20 | DM: 5/20 | Act: 2/20 | Com: 8/15 | Age: 6/15 | Call: -/10 |
| Tolmar - Fensolvi | Usaid Cheema | Qualification | 5% | €420,044 | 30% | €126,013 | At Risk | Vel: 6/20 | DM: 5/20 | Act: 2/20 | Com: 8/15 | Age: 6/15 | Call: -/10 |
| Vertex Pharmaceuticals (Ireland) Limited - Casgevy | Eran Desheh | Qualification | 5% | €500,000 | 30% | €150,000 | At Risk | Vel: 6/20 | DM: 5/20 | Act: 2/20 | Com: 8/15 | Age: 6/15 | Call: -/10 |
| VERTEX | AMKD | US - Phase 2 | Jacob Plummer | Qualification | 5% | €5,040,522 | 30% | €1,512,157 | At Risk | Vel: 6/20 | DM: 5/20 | Act: 2/20 | Com: 8/15 | Age: 6/15 | Call: -/10 |
| Walgreens/Boots | Randal Whitmore | Qualification | 5% | €420,044 | 30% | €126,013 | At Risk | Vel: 6/20 | DM: 5/20 | Act: 2/20 | Com: 8/15 | Age: 6/15 | Call: -/10 |
| Centene Patient Finder | Jacob Plummer | Qualification | 5% | €420,044 | 29% | €121,813 | Critical | Vel: 2/20 | DM: 5/20 | Act: 10/20 | Com: 8/15 | Age: 0/15 | Call: 4/10 |
| EMD Serono | MS & Rare Disease | US | Eran Desheh | Qualification | 5% | €420,044 | 29% | €121,813 | Critical | Vel: 2/20 | DM: 5/20 | Act: 10/20 | Com: 8/15 | Age: 0/15 | Call: 4/10 |
| Ipsen | Bylvay | Karen VanOverberghe | Qualification | 5% | €420,044 | 29% | €121,813 | Critical | Vel: 2/20 | DM: 5/20 | Act: 10/20 | Com: 8/15 | Age: 0/15 | Call: 4/10 |
| Jazz Pharma | Ashley Cudini | Qualification | €420,044 | 29% | €121,813 | Critical | Vel: 2/20 | DM: 5/20 | Act: 10/20 | Com: 8/15 | Age: 0/15 | Call: 4/10 |
| Lilly Lilly Direct - Patient Finder | Karen VanOverberghe | Qualification | 5% | €210,022 | 29% | €60,906 | Critical | Vel: 2/20 | DM: 5/20 | Act: 10/20 | Com: 8/15 | Age: 0/15 | Call: 4/10 |
| Pfizer | ATTR-CM | DE | Jacob Plummer | Qualification | 5% | €420,044 | 29% | €121,813 | Critical | Vel: 2/20 | DM: 5/20 | Act: 10/20 | Com: 8/15 | Age: 0/15 | Call: 4/10 |
| Trinity Life Sciences Exploration | Jacob Plummer | Qualification | 5% | €420,044 | 29% | €121,813 | Critical | Vel: 2/20 | DM: 5/20 | Act: 10/20 | Com: 8/15 | Age: 0/15 | Call: 4/10 |
| Jazz Pharmaceuticals US- Xywav | Ashley Cudini | Discovery | 10% | €420,044 | 28% | €117,612 | Critical | Vel: 2/20 | DM: 5/20 | Act: 10/20 | Com: 8/15 | Age: 0/15 | Call: 3/10 |
| Progyny | Endometriosis | US | Jacob Plummer | Qualification | 5% | €420,044 | 28% | €117,612 | Critical | Vel: 2/20 | DM: 5/20 | Act: 10/20 | Com: 8/15 | Age: 0/15 | Call: -/10 |
| Roche LatAm | Ashley Cudini | Qualification | 5% | €100,000 | 28% | €28,000 | Critical | Vel: 2/20 | DM: 5/20 | Act: 10/20 | Com: 8/15 | Age: 0/15 | Call: -/10 |
| VERTEX | AMKD | US | Ashley Cudini | Discovery | 10% | €420,044 | 28% | €117,612 | Critical | Vel: 2/20 | DM: 5/20 | Act: 10/20 | Com: 8/15 | Age: 0/15 | Call: -/10 |
| ACADIA Pharmaceuticals | Daybue | Rett syndrome | Usaid Cheema | Qualification | 5% | €420,044 | 27% | €113,412 | Critical | Vel: 2/20 | DM: 2/20 | Act: 12/20 | Com: 8/15 | Age: 0/15 | Call: -/10 |
| Acorda Therapeutics | Ampyra | Multiple sclerosis | Usaid Cheema | Qualification | 5% | €420,044 | 27% | €113,412 | Critical | Vel: 6/20 | DM: 2/20 | Act: 2/20 | Com: 8/15 | Age: 6/15 | Call: -/10 |
| Alnylam Pharmaceuticals | Amvuttra | ATTR-CM | Ashley Cudini | Qualification | 5% | €420,044 | 26% | €109,211 | Critical | Vel: 2/20 | DM: 2/20 | Act: 10/20 | Com: 8/15 | Age: 0/15 | Call: 4/10 |
| Northwestern Medicine - International | Adel Baluch | Contracting | 80% | €0 | 25% | €0 | Critical | Vel: 2/20 | DM: 5/20 | Act: 6/20 | Com: 8/15 | Age: 0/15 | Call: 4/10 |
| RVO Health | Jacob Plummer | Proposal | 30% | €840,087 | 25% | €210,022 | Critical | Vel: 2/20 | DM: 5/20 | Act: 6/20 | Com: 8/15 | Age: 0/15 | Call: 4/10 |
| argenx US Vyvgart gMG | Ashley Cudini | Discovery | 10% | €420,044 | 24% | €100,810 | Critical | Vel: 2/20 | DM: 2/20 | Act: 10/20 | Com: 8/15 | Age: 0/15 | Call: -/10 |
| Risant Health Expansion [Entity C] | Eric Harker | Qualification | 5% | €5,040,522 | 23% | €1,159,320 | Critical | Vel: 2/20 | DM: 5/20 | Act: 4/20 | Com: 8/15 | Age: 0/15 | Call: 4/10 |
| Risant Health Expansion [Entity D] | Eric Harker | Qualification | 5% | €5,040,522 | 23% | €1,159,320 | Critical | Vel: 2/20 | DM: 5/20 | Act: 4/20 | Com: 8/15 | Age: 0/15 | Call: 4/10 |
| Risant Health Expansion [Entity E] | Eric Harker | Qualification | 5% | €5,040,522 | 23% | €1,159,320 | Critical | Vel: 2/20 | DM: 5/20 | Act: 4/20 | Com: 8/15 | Age: 0/15 | Call: 4/10 |
| Risant Health Expansion [Entity F] | Eric Harker | Qualification | 5% | €5,040,522 | 23% | €1,159,320 | Critical | Vel: 2/20 | DM: 5/20 | Act: 4/20 | Com: 8/15 | Age: 0/15 | Call: 4/10 |
| Upsell - PHC / Agent | Simon Wolpert | Qualification | 5% | €1,000,000 | 23% | €230,000 | Critical | Vel: 2/20 | DM: 5/20 | Act: 6/20 | Com: 8/15 | Age: 0/15 | Call: -/10 |
| Fraser Health (vis Deloitte) - British Columbia | Simon Wolpert | Qualification | 5% | €3,252,235 | 22% | €715,492 | Critical | Vel: 2/20 | DM: 5/20 | Act: 2/20 | Com: 8/15 | Age: 0/15 | Call: 5/10 |
| Health 811 SOW9 - HCC + Survey Planning + Delivery | Simon Wolpert | Proposal | 30% | €92,921 | 22% | €20,443 | Critical | Vel: 2/20 | DM: 5/20 | Act: 2/20 | Com: 8/15 | Age: 0/15 | Call: 5/10 |
| Main Line Health | Simon Wolpert | Qualification | €1,428,148 | 22% | €314,193 | Critical | Vel: 2/20 | DM: 5/20 | Act: 2/20 | Com: 8/15 | Age: 0/15 | Call: 5/10 |
| Novo Nordisk Global Markets | Eran Desheh | Discovery | 10% | €500,000 | 22% | €110,000 | Critical | Vel: 2/20 | DM: 5/20 | Act: 2/20 | Com: 8/15 | Age: 0/15 | Call: 5/10 |
| Pharmeon | UW Zorg online | Discovery | €1,050,000 | 22% | €231,000 | Critical | Vel: 2/20 | DM: 5/20 | Act: 2/20 | Com: 8/15 | Age: 0/15 | Call: 5/10 | |
| Relevate health | Jacob Plummer | Qualification | 5% | €84,009 | 22% | €18,482 | Critical | Vel: 2/20 | DM: 5/20 | Act: 2/20 | Com: 8/15 | Age: 0/15 | Call: 5/10 |
| Salinas Valley Health | Simon Wolpert | Qualification | €1,700,000 | 22% | €374,000 | Critical | Vel: 2/20 | DM: 5/20 | Act: 2/20 | Com: 8/15 | Age: 0/15 | Call: 5/10 |
| Texas Tech University Health System | Qualification | €756,078 | 22% | €166,337 | Critical | Vel: 2/20 | DM: 5/20 | Act: 2/20 | Com: 8/15 | Age: 0/15 | Call: 5/10 | |
| NYU Langone DFD | Simon Wolpert | Qualification | 5% | €1,260,130 | 21% | €264,627 | Critical | Vel: 2/20 | DM: 5/20 | Act: 2/20 | Com: 8/15 | Age: 0/15 | Call: 4/10 |
| Patient Finder for Boots UK | Randal Whitmore | Qualification | €0 | 21% | €0 | Critical | Vel: 2/20 | DM: 5/20 | Act: 2/20 | Com: 8/15 | Age: 0/15 | Call: 4/10 |
| Saudi MoH Sehhaty App | Daniel Nathrath | Qualification | €7,085,000 | 21% | €1,487,850 | Critical | Vel: 2/20 | DM: 5/20 | Act: 2/20 | Com: 8/15 | Age: 0/15 | Call: 4/10 |
| Alberta Health Services - Patient Portal (via Orio | Simon Wolpert | Qualification | 5% | €4,800,918 | 19% | €912,174 | Critical | Vel: 2/20 | DM: 2/20 | Act: 2/20 | Com: 8/15 | Age: 0/15 | Call: 5/10 |
| BCBSA | Simon Wolpert | Qualification | €3,200,000 | 19% | €608,000 | Critical | Vel: 2/20 | DM: 5/20 | Act: 2/20 | Com: 8/15 | Age: 0/15 | Call: -/10 |
| Blue Cross Blue Shield Michigan | Simon Wolpert | Qualification | €5,040,522 | 19% | €957,699 | Critical | Vel: 2/20 | DM: 5/20 | Act: 2/20 | Com: 8/15 | Age: 0/15 | Call: -/10 |
| BridgeBio Pharma | Attruby | ATTR-CM | Ashley Cudini | Qualification | 5% | €420,044 | 19% | €79,808 | Critical | Vel: 2/20 | DM: 2/20 | Act: 2/20 | Com: 8/15 | Age: 0/15 | Call: 5/10 |
| DKV Seguros | Johannes Vonhuelsen | Discovery | 10% | €486,000 | 19% | €92,340 | Critical | Vel: 2/20 | DM: 5/20 | Act: 2/20 | Com: 8/15 | Age: 0/15 | Call: -/10 |
| Fedgroup | Johannes Vonhuelsen | Qualification | €0 | 19% | €0 | Critical | Vel: 2/20 | DM: 5/20 | Act: 2/20 | Com: 8/15 | Age: 0/15 | Call: -/10 |
| Janssen - Commercial Data Science | Qualification | €300,000 | 19% | €57,000 | Critical | Vel: 2/20 | DM: 5/20 | Act: 2/20 | Com: 8/15 | Age: 0/15 | Call: -/10 | |
| Medgate | Daniel Nathrath | Qualification | €0 | 19% | €0 | Critical | Vel: 2/20 | DM: 5/20 | Act: 2/20 | Com: 8/15 | Age: 0/15 | Call: -/10 |
| Ontario Enhancements - Suicide Pop Up - Delivery | Simon Wolpert | Qualification | 5% | €247,789 | 19% | €47,080 | Critical | Vel: 2/20 | DM: 5/20 | Act: 2/20 | Com: 8/15 | Age: 0/15 | Call: -/10 |
| Ontario SOW9 - Health Care Connect (Primary Care A | Simon Wolpert | Proposal | 30% | €30,974 | 19% | €5,885 | Critical | Vel: 2/20 | DM: 5/20 | Act: 2/20 | Com: 8/15 | Age: 0/15 | Call: -/10 |
| Ontario Upsell - FTI + Concierge | Simon Wolpert | Qualification | €7,000,000 | 19% | €1,330,000 | Critical | Vel: 2/20 | DM: 5/20 | Act: 2/20 | Com: 8/15 | Age: 0/15 | Call: -/10 |
| Saudi MoH Saned platform | Daniel Nathrath | Qualification | €900,000 | 19% | €171,000 | Critical | Vel: 2/20 | DM: 5/20 | Act: 2/20 | Com: 8/15 | Age: 0/15 | Call: -/10 |
| VA (EHR Modernization Integration Office) | Simon Wolpert | Qualification | €15,289,583 | 19% | €2,905,021 | Critical | Vel: 2/20 | DM: 5/20 | Act: 2/20 | Com: 8/15 | Age: 0/15 | Call: -/10 |